

# Leukemia/Lymphoma Protocol List

## July 2021

ALL treatment protocols			
Study	Clinical trial name	Phase/type	Age
COG AALL1631	AALL1631, International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones <a href="https://clinicaltrials.gov/ct2/show/NCT03007147">https://clinicaltrials.gov/ct2/show/NCT03007147</a>	III	>1 to ≤21 yr
COG AALL1731 <sup>REQ for B-ALL</sup>	AALL1731, A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) <a href="https://clinicaltrials.gov/ct2/show/NCT03914625">https://clinicaltrials.gov/ct2/show/NCT03914625</a>	III	≥365 days to <10 yr (B-ALL wo/DS) ≥365 days to ≤31 yr (B-ALL w/DS and B-LLy w or wo DS)
COG AALL1732 <sup>REQ for B-ALL, MPAL</sup>	AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy <a href="https://clinicaltrials.gov/ct2/show/NCT03959085">https://clinicaltrials.gov/ct2/show/NCT03959085</a>	III	>365 days to <25 yr
20140106 (formerly ONYX CFZ008)	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT02303821">https://clinicaltrials.gov/ct2/show/NCT02303821</a>	Ib/II	≤18 yr
COG AALL1521 [Incyte]	INCB 18424-269: A Phase 2 Study of JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-rearranged and/or JAK Pathway-mutant Acute Lymphoblastic Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT02723994">https://clinicaltrials.gov/ct2/show/NCT02723994</a>	II	>1 to ≤21 yr
COG AALL1621	AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) <a href="https://clinicaltrials.gov/ct2/show/NCT02981628">https://clinicaltrials.gov/ct2/show/NCT02981628</a>	II	≥1 to <22 yr
Novartis Cassiopeia (AALL1721)	A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy <a href="https://clinicaltrials.gov/ct2/show/NCT03876769">https://clinicaltrials.gov/ct2/show/NCT03876769</a>	II	1 to 25 yr
COG ADV1823	ADV1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias <a href="https://clinicaltrials.gov/ct2/show/NCT03834961">https://clinicaltrials.gov/ct2/show/NCT03834961</a>	II	≤30 yr

<b>JNJ Daratumumab</b>	An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects $\geq 1$ and $\leq 30$ Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT03384654">https://clinicaltrials.gov/ct2/show/NCT03384654</a>	II	$\geq 1$ to $\leq 30$ yr
<b>Novartis CART ELIANA</b>	Protocol CCTL019B2202: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients with Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT02435849">https://clinicaltrials.gov/ct2/show/NCT02435849</a>	II	$\geq 3$ to $\leq 21$ yr
<b>Novartis CART FU</b>	Protocol No. CCTL019A2205B: Long Term Follow-up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy <a href="https://clinicaltrials.gov/ct2/show/NCT02445222">https://clinicaltrials.gov/ct2/show/NCT02445222</a>	NA	any age (received anti-CD19 directed CART therapy)
<b>TACL 2012-002</b>	A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT02879643">https://clinicaltrials.gov/ct2/show/NCT02879643</a>	Pilot	$\geq 1$ to $\leq 21$ yr
<b>TACL 2017-002</b>	A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT03817320">https://clinicaltrials.gov/ct2/show/NCT03817320</a>	I/II	$\leq 21$ yr
<b>AflacLL1602 ENCERT</b>	ENCERT: A Phase 1 Trial using Everolimus in combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia/Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT03328104">https://clinicaltrials.gov/ct2/show/NCT03328104</a>	I	$>1$ to $<30$ yr
<b>DFCI 18-328</b>	Phase I Trial of Ribociclib in Combination with Everolimus and Dexamethasone in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia	I	$>12$ mo to $\leq 30$ yr
<b>ALL biology, supportive treatment and non-therapeutic protocols</b>			
<b>Study</b>	<b>Clinical trial name</b>	<b>Phase/type</b>	<b>Age</b>
<b>AflacPM1702</b>	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	$<30$ yr
<b>CCPS</b>	Childhood Cancer Predisposition Study (CCPS) <a href="https://clinicaltrials.gov/ct2/show/NCT04511806">https://clinicaltrials.gov/ct2/show/NCT04511806</a>	Non-therapeutic	$<21$ yr primary subj
<b>NCICOVID</b>	NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study <a href="https://clinicaltrials.gov/ct2/show/NCT04387656">https://clinicaltrials.gov/ct2/show/NCT04387656</a>	Non-therapeutic	Any age

<b>COG APEC14B1</b>	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study <a href="https://clinicaltrials.gov/ct2/show/NCT02402244">https://clinicaltrials.gov/ct2/show/NCT02402244</a>	Non-therapeutic	≤25 yr
<b>COG ALTE03N1</b>	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 <a href="https://clinicaltrials.gov/ct2/show/NCT00082745">https://clinicaltrials.gov/ct2/show/NCT00082745</a>	Non-therapeutic	≤21 yr at dx
<b>COG ALTE05N1</b>	Umbrella Long-Term Follow-Up Protocol <a href="https://clinicaltrials.gov/ct2/show/NCT00736749">https://clinicaltrials.gov/ct2/show/NCT00736749</a>	Non-therapeutic	All ages
<b>COG ALTE07C1</b>	ALTE07C1, Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer <a href="https://clinicaltrials.gov/ct2/show/NCT00772200">https://clinicaltrials.gov/ct2/show/NCT00772200</a>	Non-therapeutic	3 to <22 yr
<b>COG ALTE1631</b>	ALTE1631, A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT03223753">https://clinicaltrials.gov/ct2/show/NCT03223753</a>	NA	≥8 to ≤16 yr
<b>Telehealth Home-based Transition</b>	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr
<b>AML treatment protocols</b>			
<b>Study</b>	<b>Clinical trial name</b>	<b>Phase/type</b>	<b>Age</b>
<b>Pfizer B1761031 Mylotarg</b>	A Single Arm, Open-label, Phase 4 Study Evaluating QT Interval, Pharmacokinetics, and Safety of Gemtuzumab Ozogamicin (Mylotarg) as a Single-agent Regimen in Patients with Relapsed or Refractory CD33-positive Acute Myeloid Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT03727750">https://clinicaltrials.gov/ct2/show/NCT03727750</a>	IV	>12 yr
<b>COG AAML1531</b>	Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome <a href="https://clinicaltrials.gov/ct2/show/NCT02521493">https://clinicaltrials.gov/ct2/show/NCT02521493</a>	III	>90 days to <4 yr
<b>AAML1831<sup>REQ</sup></b>	AAML1831, A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations <a href="https://clinicaltrials.gov/ct2/show/NCT04293562">https://clinicaltrials.gov/ct2/show/NCT04293562</a>	III	<22 yr
<b>COG ADVL1521</b>	ADVL1521: A Phase 2 Study of the MEK Inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT03190915">https://clinicaltrials.gov/ct2/show/NCT03190915</a>	II	≥2 to <22 yr
<b>COG ADVL1823</b>	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias <a href="https://clinicaltrials.gov/ct2/show/NCT03834961">https://clinicaltrials.gov/ct2/show/NCT03834961</a>	II	≤30 yr

<b>AC220-A-U202 (ADVL1822)</b>	A Phase 1/2, Multi-center, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib Administered in Combination with Re-induction Chemotherapy, and as a Single-agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD Mutations <a href="https://clinicaltrials.gov/ct2/show/NCT03793478">https://clinicaltrials.gov/ct2/show/NCT03793478</a>	I/II	≥1 mo to <21 yr
<b>TACL 2016-002</b>	TACL2016-002: A TACL Phase 1/2 Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia (BMS reference CA209-9JY)	I/II	>1 to ≤30 yr
<b>AAML18P1</b>	Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP) <a href="https://clinicaltrials.gov/ct2/show/NCT03817398">https://clinicaltrials.gov/ct2/show/NCT03817398</a>	Pilot	<18 yr at diag; <25 yr at enroll
<b>PEPN1812</b>	PEPN1812: A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia <a href="https://clinicaltrials.gov/ct2/show/NCT04158739">https://clinicaltrials.gov/ct2/show/NCT04158739</a>	I	<21 yr

#### AML biology, supportive treatment and non-therapeutic protocols

Study	Clinical trial name	Phase/type	Age
<b>AflacPM1702</b>	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
<b>CCPS</b>	Childhood Cancer Predisposition Study (CCPS) <a href="https://clinicaltrials.gov/ct2/show/NCT04511806">https://clinicaltrials.gov/ct2/show/NCT04511806</a>	Non-therapeutic	<21 yr primary subj
<b>NCICOVID</b>	NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study <a href="https://clinicaltrials.gov/ct2/show/NCT04387656">https://clinicaltrials.gov/ct2/show/NCT04387656</a>	Non-therapeutic	Any age
<b>COG ALTE05N1</b>	Umbrella Long-Term Follow-Up Protocol <a href="https://clinicaltrials.gov/ct2/show/NCT00736749">https://clinicaltrials.gov/ct2/show/NCT00736749</a>	Non-therapeutic	All ages
<b>Arnold PCORI</b>	Home of Away from Home: Comparing Clinical Outcomes Relevant to the Care of Pediatric Acute Myeloid Leukemia during Periods of Neutropenia [Aim 3 closed to accrual; Aim 1 open] <a href="https://clinicaltrials.gov/ct2/show/NCT02774850">https://clinicaltrials.gov/ct2/show/NCT02774850</a>	Non-therapeutic	Any age
<b>Telehealth Home-based Transition</b>	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr

#### NHL treatment protocols

Study	Clinical trial name	Phase/type	Age
-------	---------------------	------------	-----

<p><b>COG</b> <b>AALL1731</b> <small>REQ for B-ALL</small></p>	<p>AALL1731, A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) <a href="https://clinicaltrials.gov/ct2/show/NCT03914625">https://clinicaltrials.gov/ct2/show/NCT03914625</a></p>	<p>III</p>	<p>≥365 days to &lt;10 yr (B-ALL wo/DS) ≥365 days to ≤31 yr (B-ALL w/DS and B-LLy w or wo DS)</p>
<p><b>COG</b> <b>AALL1732</b> <small>REQ for B-ALL, MPAL</small></p>	<p>AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy <a href="https://clinicaltrials.gov/ct2/show/NCT03959085">https://clinicaltrials.gov/ct2/show/NCT03959085</a></p>	<p>III</p>	<p>&gt;365 days to &lt;25 yr</p>
<p><b>COG</b> <b>ANHL12P1</b></p>	<p>A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC#749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND #117117 <a href="https://clinicaltrials.gov/ct2/show/NCT01979536">https://clinicaltrials.gov/ct2/show/NCT01979536</a></p>	<p>II</p>	<p>&lt;22 yr</p>
<p><b>COG</b> <b>APEC1621A</b> <small>REQ</small></p>	<p>APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions <a href="https://clinicaltrials.gov/ct2/show/NCT03213704">https://clinicaltrials.gov/ct2/show/NCT03213704</a></p>	<p>II</p>	<p>≥12 mo to ≤21 yr</p>
<p><b>COG</b> <b>APEC1621B</b> <small>REQ</small></p>	<p>APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations <a href="https://clinicaltrials.gov/ct2/show/NCT03210714">https://clinicaltrials.gov/ct2/show/NCT03210714</a></p>	<p>II</p>	<p>≥12 mo to ≤21 yr</p>
<p><b>COG</b> <b>APEC1621D</b> <small>REQ</small></p>	<p>APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors <a href="https://clinicaltrials.gov/ct2/show/NCT03213678">https://clinicaltrials.gov/ct2/show/NCT03213678</a></p>	<p>II</p>	<p>≥12 mo to ≤21 yr</p>
<p><b>COG</b> <b>APEC1621F</b> <small>REQ</small></p>	<p>APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations <a href="https://clinicaltrials.gov/ct2/show/NCT03213652">https://clinicaltrials.gov/ct2/show/NCT03213652</a></p>	<p>II</p>	<p>≥12 mo to ≤21 yr</p>
<p><b>COG</b> <b>APEC1621G</b> <small>REQ</small></p>	<p>APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations <a href="https://clinicaltrials.gov/ct2/show/NCT03220035">https://clinicaltrials.gov/ct2/show/NCT03220035</a></p>	<p>II</p>	<p>≥12 mo to ≤21 yr</p>
<p><b>COG</b> <b>APEC1621H</b> <small>REQ</small></p>	<p>APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes <a href="https://clinicaltrials.gov/ct2/show/NCT03233204">https://clinicaltrials.gov/ct2/show/NCT03233204</a></p>	<p>II</p>	<p>≥12 mo to ≤21 yr</p>

<b>COG APEC1621I<sup>REQ</sup></b>	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes <a href="https://clinicaltrials.gov/ct2/show/NCT03526250">https://clinicaltrials.gov/ct2/show/NCT03526250</a>	II	≥12 mo to ≤21 yr
<b>COG APEC1621J<sup>REQ</sup></b>	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations <a href="https://clinicaltrials.gov/ct2/show/NCT03698994">https://clinicaltrials.gov/ct2/show/NCT03698994</a>	II	≥12 mo to ≤21 yr
<b>COG ADVL1721</b>	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT03458728">https://clinicaltrials.gov/ct2/show/NCT03458728</a>	I/II	≥6 mo to ≤21 yr
<b>COG ADVL1414</b>	ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors <a href="https://clinicaltrials.gov/ct2/show/NCT02323880">https://clinicaltrials.gov/ct2/show/NCT02323880</a>	I	≥12 mo to ≤21 yr
<b>AbbVie M13-833</b>	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies <a href="https://clinicaltrials.gov/ct2/show/NCT03236857">https://clinicaltrials.gov/ct2/show/NCT03236857</a>	I	<25 yr
<b>NHL biology, supportive treatment and non-therapeutic protocols</b>			
<b>Study</b>	<b>Clinical trial name</b>	<b>Phase/type</b>	<b>Age</b>
<b>AflacPM1702</b>	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
<b>CCPS</b>	Childhood Cancer Predisposition Study (CCPS) <a href="https://clinicaltrials.gov/ct2/show/NCT04511806">https://clinicaltrials.gov/ct2/show/NCT04511806</a>	Non-therapeutic	<21 yr primary subj
<b>NCICOVID</b>	NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study <a href="https://clinicaltrials.gov/ct2/show/NCT04387656">https://clinicaltrials.gov/ct2/show/NCT04387656</a>	Non-therapeutic	Any age
<b>COG ALTE03N1</b>	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 <a href="https://clinicaltrials.gov/ct2/show/NCT00082745">https://clinicaltrials.gov/ct2/show/NCT00082745</a>	Non-therapeutic	≤21 yr at dx
<b>COG ALTE05N1</b>	Umbrella Long-Term Follow-Up Protocol <a href="https://clinicaltrials.gov/ct2/show/NCT00736749">https://clinicaltrials.gov/ct2/show/NCT00736749</a>	Non-therapeutic	All ages
<b>Telehealth Home-based Transition</b>	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr
<b>Hodgkin disease treatment protocols</b>			
<b>Study</b>	<b>Clinical trial name</b>	<b>Phase/type</b>	<b>Age</b>
<b>SWOG S1826</b>	A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (Age ≥12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT03907488">https://clinicaltrials.gov/ct2/show/NCT03907488</a>	III	≥12 yr

<b>COG AHOD1721 CA209744</b>	Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/refractory (R/R) CD30 + Classic Hodgkin lymphoma (cHL) after Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response <a href="https://clinicaltrials.gov/ct2/show/NCT02927769">https://clinicaltrials.gov/ct2/show/NCT02927769</a>	II	5 to 30 yr
<b>COG AHOD1822 (MK3475-667)</b>	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667) <a href="https://clinicaltrials.gov/ct2/show/NCT03407144">https://clinicaltrials.gov/ct2/show/NCT03407144</a>	II	≥3 to ≤25 yr
<b>COG ADVL1721</b>	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT03458728">https://clinicaltrials.gov/ct2/show/NCT03458728</a>	I/II	≥6 mo to ≤21 yr
<b>COG ADVL1414</b>	ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors <a href="https://clinicaltrials.gov/ct2/show/NCT02323880">https://clinicaltrials.gov/ct2/show/NCT02323880</a>	I	≥12 mo to ≤21 yr
<b>E4412</b>	A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma <a href="https://clinicaltrials.gov/ct2/show/NCT01896999">https://clinicaltrials.gov/ct2/show/NCT01896999</a>	II	≥12 yr

**Hodgkin disease biology, supportive treatment and non-therapeutic protocols**

<b>Study</b>	<b>Clinical trial name</b>	<b>Phase/type</b>	<b>Age</b>
<b>AflacPM1702</b>	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
<b>CCPS</b>	Childhood Cancer Predisposition Study (CCPS) <a href="https://clinicaltrials.gov/ct2/show/NCT04511806">https://clinicaltrials.gov/ct2/show/NCT04511806</a>	Non-therapeutic	<21 yr primary subj
<b>NCICOVID</b>	NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study <a href="https://clinicaltrials.gov/ct2/show/NCT04387656">https://clinicaltrials.gov/ct2/show/NCT04387656</a>	Non-therapeutic	Any age
<b>COG ALTE05N1</b>	Umbrella Long-Term Follow-Up Protocol <a href="https://clinicaltrials.gov/ct2/show/NCT00736749">https://clinicaltrials.gov/ct2/show/NCT00736749</a>	Non-therapeutic	All ages
<b>Telehealth Home-based Transition</b>	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr